“The company was informed by the USFDA that the agency placed its phase 2/3 immuno-bridging and broadening study for Covaxin (BBV152), OCU-002, on clinical hold,” Ocugen said in a statement., “The company was informed by the USFDA that the agency placed its phase 2/3 immuno-bridging and broadening study for Covaxin (BBV152), OCU-002, on clinical hold,” Ocugen said in a statement., , Read More
AAS Yoga
Go for Euphoria – Illness to Wellness the Natural Way